IL7 and neoplasm: In the adjuvant setting, tumor-bearing mice treated with dex and IL-7 post-CAR T cell infusion had superior survival outcomes compared with mice treated with dex or IL-7 alone after CAR T cell infusion in both dex-sensitive and dex-insensitive tumor models.